Investors

TSXV: NRX

From acute injury to functional recovery

Nurexone's mission is to pioneer development of novel, biologic and minimally-invasive treatment for Spinal Cord and Traumatic Brain Injuries

We're developing a nanocarrier - based platform that uses exosomes to deliver specialized therapeutic compounds to the body.

Get Investor Updates

In THE MEDIA

July 18, 2022
FXSTREET
New TSXV listing looks to address the $3B spinal cord injury treatment market (NRX.V)
July 13, 2022
TechBullion
NurExone begins trading on the TSXV, bringing a glimmer of hope to SCI Patients